H.C. Wainwright Gives Phio Pharmaceuticals a Buy Rating

Summary

Phio Pharmaceuticals’ stock increased by 12.4% in pre-market trading to $2.36 after H.C. Wainwright initiated coverage with a ‘buy’ rating and a target price of $14, suggesting a potential sevenfold increase from the previous closing price. The brokerage expressed optimism about the company’s key skin cancer treatment PH-762’s clinical activity and safety, and emphasized the importance of maintaining open collaboration opportunities in the current market.Reuters

Impact Analysis

The event is at the company level, impacting Phio Pharmaceuticals directly. Insights from the inference graphs include:

1. Information Node: H.C. Wainwright’s buy rating and target price of $14, highlighting optimism about Phio’s PH-762 treatment.
2. First-Order Effects: Immediate stock price increase of 12.4%, reflecting investor confidence following the rating.Reuters
3. Second-Order Effects: Possible increased interest in the company’s collaboration opportunities and further investment in clinical trials.
   Investment Opportunities: Consideration of Phio Pharmaceuticals’ stock as a potential investment, gauging future performance based on clinical advancements and market collaborations. Historical context shows recent insider buying, indicating confidence in the company’s prospects.Reuters